Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis
Phase 1
Recruiting
- Conditions
- Nonalcoholic SteatohepatitisNonalcoholic Fatty Liver
- Interventions
- Drug: OA-235i (4 mg)Drug: OA-235i (8 mg)Drug: OA-235i Dose 3Drug: OA-235i Escalating Dose 4Drug: OA-235i Escalating Dose 5Drug: OA-235i Multiple Dose
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Oasis Pharmaceuticals, LLC
- Target Recruit Count
- 23
- Registration Number
- NCT05680233
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath